Fresenius Medical Care AG
Close on Oct 19, 2026
- Market cap
- $5.89B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Fresenius Medical Care has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Fresenius Medical Care filed with the SEC
Fresenius Medical Care Announces Publication of a Multinational
EX-99.1 to Form 6-K
Fresenius Medical Care appoints Cassie McLean as new Management
EX-99.1 to Form 6-K
Fresenius Medical Care accelerates income growth to 23% in the
EX-99.1 to Form 6-K
Statement of earnings page 2
EX-99.2 to Form 6-K
HEADLINE: Fresenius Medical Care reports operating income excluding
EX-99.1 to Form 6-K
Bad Homburg v.d. Höhe, May 28, 2026
EX-99.1 to Form 6-K
Fresenius Medical Care launches first
EX-99.2 to Form 6-K
Fresenius Medical Care Annual General Meeting: Strengthening performance
EX-99.1 to Form 6-K
49(1), sentence 1, no. 2
EX-99.2 to Form 6-K
49(1), sentence 1, no. 2
EX-99.3 to Form 6-K
OF THE FIRST QUARTER 2026
EX-99.2 to Form 6-K
Report for the fiscal year 2025
EX-99.2 to Form 6-K
Report by the Supervisory Board
EX-99.3 to Form 6-K
Report on Form 20-F for fiscal year 2025
EX-99.1 to Form 6-K
Fresenius Medical Care delivers 27% earnings growth in 2025 and
EX-99.1 to Form 6-K
OVERVIEW OF THE FOURTH QUARTER AND FULL YEAR 2025
EX-99.2 to Form 6-K
Fresenius Medical Care AG is continuing its
EX-99.1 to Form 6-K
Fresenius Medical Care accelerates the second
EX-99.2 to Form 6-K
Fresenius Medical Care appoints Charles
EX-99.1 to Form 6-K
Fresenius Medical Care further accelerates organic revenue development
EX-99.1 to Form 6-K
Statement of earnings page 2
EX-99.2 to Form 6-K
Fresenius Medical Care appoints Joseph Turk as new Management Board
EX-99.1 to Form 6-K
Fresenius Medical Care advances its FME Reignite strategy by increasing
EX-99.1 to Form 6-K
Bad Homburg v.d. Höhe, August 11, 2025
EX-99.1 to Form 6-K
Fresenius Medical Care announces first tranche of its share buyback
EX-99.2 to Form 6-K
Fresenius Medical Care delivers strong organic revenue growth and
EX-99.1 to Form 6-K
OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2025
EX-99.2 to Form 6-K
Fresenius Medical Care AG resolves share buyback
EX-99.1 to Form 6-K
Fresenius Medical Care Launches its Strategy FME Reignite with increased
EX-99.2 to Form 6-K
Fresenius Medical Care Begins Broader U.S. Commercialization of
EX-99.1 to Form 6-K
Fresenius Medical Care Annual General Meeting: Strong Performance
EX-99.1 to Form 6-K
Notification pursuant to Section 49 (1) sentence
EX-99.2 to Form 6-K
Countermotions submitted by the Association
EX-99.1 to Form 6-K